| |
LVEF ≥ 30%n=232 |
LVEF<30%n=157 |
p |
| Age, y |
57 ± 10 |
57 ± 10 |
ns |
| Male, n% |
189 (81%) |
137 (86%) |
ns |
| BMI, kg/m2 |
24 ± 3 |
25 ± 3 |
ns |
| Hypertension, n% |
105 (45%) |
70 (44%) |
ns |
| Smocking, n% |
122 (53%) |
123 (78%) |
<0.01 |
| Dyslipidemia, n% |
144 (62%) |
82 (52%) |
<0.01 |
| Diabetes, n% |
49 (21%) |
41 (26%) |
ns |
| Medical treatment: |
|
|
|
| Beta-blocker, n% |
205 (88%) |
137 (87%) |
ns |
| ACE-inhibitor, n% |
207 (89%) |
116 (74%) |
<0.01 |
| Nitrates, n% |
101 (44%) |
70 (49%) |
ns |
| Ca-antagonist, n% |
49 (21%) |
35 (16%) |
<0.05 |
| Diuretic, n% |
189 (81%) |
130 (83%) |
ns |
| Statin, n% |
120 (52%) |
78 (50%) |
ns |
| Total cholesterol, mg/dl |
192 ± 48 |
193 ± 50 |
ns |
| HDL cholesterol, mg/dl |
45 ± 13 |
45 ± 13 |
ns |
| Triglycerides, mg/dl |
144 ± 64 |
155 ± 59 |
ns |
| Creatinine, mg/dl |
1.4 ± 0.4 |
1.9 ± 0.7 |
<0.05 |
| WBC, n/ul |
7460 ± 1286 |
7845 ± 1326 |
ns |
| Hemoglobin, g/l |
12.4 ± 2.4 |
11.1 ± 2.5 |
ns |
| sRAGE, ng/ml |
690 (534-1143) |
580 (356-780) |
<0.05 |
|
